



## Minnesota Department of **Human Services**

---

### **Drug Formulary Committee: Minutes of June 3, 2014 Public Meeting**

#### **Members in attendance**

Monica Brands, RPh., Stacey Ness, Pharm.D., Kelly Ruby, Pharm.D., Al Heaton, RPh., Kathryn Lombardo, M.D., James Phillips, M.D., Dan Tomaszewski Pharm.D. Margaret Artz, RPh, Ph.D.

#### **DHS staff present**

Adam Pavek, PharmD., Sara Drake, RPh., MPH, MBA

#### **Others in attendance**

Nina Bandali, Pharm.D., Katie Counts, Pharm.D.

#### **Report of the Chair**

In respect of time the chair bypassed the report of the chair.

#### **Approval of the minutes**

Minutes from the February 2014 meeting were reviewed and approved.

#### **Old Business**

During the February DFC meeting Tivicay was reviewed for continuation of prior authorization. Tivicay is a new integrase strand transfer inhibitor indicated in combination with other antiretroviral agents for the treatment of HIV.

The committee recommended to the department that Tivicay remain on PA by a unanimous vote. The committee recommended that Tivicay be re-reviewed in 3 months.

The Department, with the help of a University of New Mexico student Briana Coyne, completed a utilization review to determine appropriate use of Tivicay in an MHCP population. DHS met with regional clinical experts and reviewed current utilization patterns to help inform Tivicay prior authorization drug use policy.

The review concluded that appropriate utilization management would include a quantity limit, ensuring twice daily treatment be reserved for patients using certain medications with certain mutations. ( INSTI and treatment experienced patients, INSTI resistance and co-administration with EFV, rifampin, tipranavir, fosamprenavir ) and that the prior authorization be removed. The committee agreed with the department's assessment.

#### **New Business**

##### ***Class Reviews***

**Short-Acting Beta Agonists:** The committee discussed SABA agents in a class review format. Short-acting beta-agonists are indicated for the treatment and prevention of bronchospasm. The committee recommended managing the category based on cost and requiring patients on Ventolin be converted to a preferred agent; ProAir or Proventil.

**New Drug PA Criteria:** The committee discussed new drug PA criteria. The Department recommended expanding the current new drug PA criteria to include criteria for 3 new categories: kits/dosepaks, new salts

of existing drugs, and self-injectable if oral formulation exists. The committee recommended adopting the expansion categories to the new drug PA criteria and agreed with the departments criteria.

#### ***New Drugs for Continued PA***

The committee discussed ANORO ELLIPTA (fluticasone furoate and vilanterol trifenate) powder [GlaxoSmithKline LLC]. The committee recommended to the department that Anoro Ellipta remain on PA by a unanimous vote. The committee recommended that clinical criteria require on-label use and the trial and failure of 2 preferred products.

The committee discussed ZOHYDRO ER (hydrocodone bitartrate) extended release capsule, [Zogenix, Inc.] The committee recommended to the department that Zohydro remain on PA by a unanimous vote and agreed with the Department's proposed clinical criteria: Patient has a diagnosis of chronic pain AND Provider is a physician certified in Pain Management AND Provider attests that the Prescription Monitoring Program has been reviewed and provides date of review AND Patient tried morphine ER and found to be intolerant to morphine ER AND Patient has tried and failed oxycodone ER AND Patient has tried and failed fentanyl AND Patient has tried and failed hydrocodone ER AND Patient has tried and failed oxymorphone ER AND Provider has submitted a patient specific pain management plan AND Patient and Provider documented in the pain management plan that the patient will abstain from alcohol.

The committee discussed APTIOM (eslicarbazepine acetate) [Sunovion Pharmaceuticals, Inc.] The committee recommended to the department that Aptiom remain on PA by a unanimous vote.

The committee discussed FYCOMPA [Eisai Inc.]. The committee recommended to the department that Fycompa remain on PA by a unanimous vote.

The committee discussed TROKENDI XR (topiramate) capsule, extended release [Supernus Pharmaceuticals, Inc.] extended release capsule. The committee recommended to the department that Trokendi XR remain on PA by a unanimous vote.

The committee discussed KHEDEZLA EXTENDED-RELEASE (desvenlafaxine) tablet [Par Pharmaceutical Inc.]. The committee recommended to the department that Khedezla remain on PA by a unanimous vote.

The committee discussed FARXIGA (dapagliflozin) tablet [E.R. Squibb & Sons, L.L.C.] The committee recommended to the department that Farxiga remain on PA by a unanimous vote. The committee recommended clinical criteria similar to other similar agents and require Invokana trial and failure.

The committee discussed HETLIOZ (tasimelteon) capsule [Vanda Pharmaceuticals Inc.] The committee recommended to the department that Hetlio remain on PA by a unanimous vote. The committee recommended clinical criteria include the failure of two preferred sedative hypnotics and that the patient be evaluated by a board certified sleep specialist.

#### ***New Specialty Drugs for Continued PA***

The committee discussed MODERIBA (ribavirin) tablet, [AbbVie Inc.] The committee recommended to the department that Moderiba remain on PA by a unanimous vote.

The committee discussed OTREXUP (methotrexate) injection, solution [Antares Pharma, Inc.] The committee recommended to the department that Olysio remain on PA by a unanimous vote.

#### **Adjournment**

The meeting was adjourned at 8:05 pm CST.